Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 2, 2004, Pages 182-186

  Kim, Jee Eun ^a   Lee, Kyu Taek ^a,b   Lee, Jong Kyun ^a   Paik, Seung Woon ^a   Rhee, Jong Chul ^a   Choi, Kyoo Wan ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Carbohydrate antigen 19 9; Pancreatic cancer; Screening test

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HEALTH CENTER; HEALTH PROMOTION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PANCREAS CANCER; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SCREENING TEST; SYMPTOM;

EID: 1342289673     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03219.x     Document Type: Article

References (26)

1. Atkinson BF, Ernst CS, Herlyn M et al. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res. 1982; 42: 4820-3.
2. Arends JW, Verstynen C, Bosman FT et al. Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma 1983; 2: 219-29.
3. Koprowski H, Steplewski Z, Mitchell K et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat. Cell Mol. Genet. 1979; 5: 957-71.
4. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann. Clin. Biochem. 1998; 35: 364-70.
5. Safi F, Roscher R, Beger HG. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9. Hepatogastroenterology 1989; 36: 419-23.
6. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am. J. Gastroenterol. 1990; 85: 350-5.
7. Pleskow DK, Berger HJ, Gyves J et al. Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann. Intern. Med. 1989; 110: 704-9.
8. Hayakawa T, Kondo T, Shibata T et al. Sensitive serum markers for detecting pancreatic cancer. Cancer 1988; 61: 1827-31.
9. Schmiegel W. Tumor markers in pancreatic cancer -current concepts. Hepatogastroenterology 1989; 36: 446-9.
10. Pagano M, Gauvreau K. Principles of biostatics, 1st edn. Belmont: Duxbury Press, 1993.
11. Del Villano BC, Brennan S, Brock P et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin. Chem. 1983; 29: 549-52.
12. Robert HF, Suzanne WF, Edward HW. Determinants of predictive value. In: Clinical epidemiology: The Essentials, 2nd edn. Baltimore: Williams & Wilkins, 1988; 56-8.
13. National health Insurance Corporation. National Health Insurance Statistical Yearbook, 1999, vol. 21. 2000; 350-563.
14. Safi F, Beger HG, Bittner R et al. CA 19-9 and pancreatic adenocarcinoma. Cancer 1986; 57: 779-83.
15. Richter JM, Christensen MR, Rustgi AK et al. The clinical utility of the CA 19-9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss. A cost-effectiveness analysis. Arch. Intern. Med. 1989; 149: 2292-7.
16. Myung SJ, Choi SM, Kim EO et al. The diagnostic value of CA 19-9 in pancreaticobiliary diseases. Korean J. Gastroenterol. 1995; 27: 345-53.
17. Schmiegel WH, Kreiker C, Eberl W et al. Monoclonal antibody defines CA 19-9 in pancreatic juices and sera. Gut 1985; 26: 456-60.
18. Sakahara H, Endo K, Nakajima K et al. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986; 57: 1324-6.
19. Itzkowitz SH, Kim YS. New carbohydrate tumor markers. Gastroenterology 1986; 90: 491-4.
20. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig. Dis. Sci. 1988; 33: 1223-5.
21. Beretta E, Malesci. A, Zerbi A et al. Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 1987; 60: 2428-31.
22. Satake K, Takeuchi T, Homma T et al. CA 19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 1994; 9: 703-6.
23. Moossa AR, Levin B. The diagnosis of 'early' pancreatic cancer: the University of Chicago experience. Cancer 1981; 47 (Suppl. 6): 1688-97.
24. Gowland M, Kalantzis N, Warwick F et al. Relative efficiency and predictive value of ultrasonography and endoscopic retrograde pancreatography in diagnosis of pancreatic disease. Lancet 1981; 2: 190-3.
25. Frebourg T, Bercoff E, Manchon N et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988; 62: 2287-90.
26. Fabris C, Del Favero G, Basso D et al. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach. Am. J. Gastroenterol 1988; 83: 549-53.